OncLive
OncLive, Plainsboro, NJ. 16K likes. OncLive covers every angle of your oncology practice, from new technology to treatment advances to important regulatory decisions
OncLive, Plainsboro, NJ. 16K likes. OncLive covers every angle of your oncology practice, from new technology to treatment advances to important regulatory decisions
A study by Sylvester Comprehensive Cancer Center assessed the outcomes of a community-based effort to test for and eradicate H. pylori, a major risk factor…
The European Commission has approved enzalutamide as monotherapy and in combination with ADT in BCR nonmetastatic hormone-sensitive prostate cancer.
The European Medicines Agency has granted orphan drug designation to annamycin for the treatment of patients with acute myeloid leukemia.
Paul G. Richardson, MD, speaks on the FDA’s decision to withdraw the approval of melflufen plus dexamethasone in multiple myeloma.
The FDA has approved the optical imaging agent Lumisight and the Lumicell Direct Visualization System for use in fluorescence imaging in breast cancer.
Real-world treatment with zanubrutinib was linked to longer treatment persistence, duration, and time to discontinuation in mantle cell lymphoma.
Abdulrahman Sinno, MD, highlights key trials that have impacted the treatment paradigm in endometrial and ovarian cancer throughout 2023.
Belumosudil elicited sustained responses and generated no new safety signals in patients with chronic graft-vs-host disease.
The database of the phase 1/2 trial of EO2401 in combination with nivolumab with or without bevacizumab in recurrent glioblastoma has locked.
Etienne Garin, MD, PhD, details how the PROACTIF study was conducted and how Y-90 Glass Microspheres could fill an unmet need for patients with hepatocellular…